ARW ON RNA

As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery.
OUR EXPERT NETWORK
-
MHRA Issues New Regulation On Modular And Point Of Care Manufacture Of ATMPs
The U.K.'s MHRA has issued a new regulation to allow for decentralized manufacturing of cell and gene therapies (advanced therapeutic medicinal products), describing modular and point of care manufacturing. It becomes effective July 23, 2025.
-
Understanding The New U.K. MHRA 'Draft Guideline On Individualised mRNA Cancer Immunotherapies'
The U.K.'s MHRA has released a new draft guideline outlining best practices for drug product design, CMC, and manufacturing of mRNA cancer immunotherapies using LNP delivery systems. The public comment period ends March 31.
-
Tessera Therapeutics Advances In Vivo Gene Therapy For SCD
Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from of the Bill & Melinda Gates Foundation to support their efforts.
-
10 Ways To Speed Up CMC In Early-Stage Drug Product Development
The inherent complexity of living cell-based products, vector-based gene therapies, and highly sensitive analytical methods demands robust change management strategies.
-
What Do We (Really) Know About DNA Quality For In Vitro Transcription?
Gene therapies and nucleic acid medicines are dependent upon a starting DNA template that defines the protein or antigen. The sequence of this template DNA being correct is critical.
WEBINARS
MEET ARW
I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
ARW ON BUSINESS OF BIOTECH
-
In close partnership with Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA's Anna Rose Welch to learn about the venture, dubbed the Johns Hopkins University RNA Innovation Center.
-
Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, an mRNA startup. The episode explores Exsilio's foundation, scientific focus, team recruitment, and its $82 million Series A funding led by Novartis Venture Fund and Delos Capital, with support from prominent investors like OrbiMed, CRISPR Therapeutics, and J.P. Morgan Life Sciences Private Capital.
-
Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business of Biotech surely will. Tune in to the first installment of this two-part episode for insight from the early days of mRNA that you probably haven't heard before.
-
This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.
-
Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception.
-
As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O", RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.
VIRTUAL EVENTS
- Accelerating mRNA-LNP Development: A Deep Dive Into Analytical & Manufacturing Technology Innovation
- Navigating The Outsourcing Paradigm For RNA Modalities
- Achieving Next-Generation mRNA-LNP Therapeutics Delivery
- From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain
- Can We Do Better? Current & Future Realities of mRNA Process Development
- Opening The "Black Box" Of The mRNA Regulatory Paradigm
NEWSLETTER ARCHIVE
- 03.24.25 -- Oncology CRO Services
- 03.21.25 -- Advancements In The Global Clinical Trial Landscape
- 03.19.25 -- DNA Quality For IVT: What Do We (Really) Know?
- 03.18.25 -- Exploring The Benefits Of Novel Nucleases In CRISPR Therapies
- 03.12.25 -- How Are The Costs Of mRNA-LNP Manufacturing Evolving?
- 03.05.25 -- The Latest & Greatest Innovations In mRNA-LNP production